These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

365 related items for PubMed ID: 25307964

  • 21. A randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassemia major.
    Aydinok Y, Ulger Z, Nart D, Terzi A, Cetiner N, Ellis G, Zimmermann A, Manz C.
    Haematologica; 2007 Dec; 92(12):1599-606. PubMed ID: 18055982
    [Abstract] [Full Text] [Related]

  • 22. Relation of chelation regimes to cardiac mortality and morbidity in patients with thalassaemia major: an observational study from a large Greek Unit.
    Ladis V, Chouliaras G, Berdoukas V, Moraitis P, Zannikos K, Berdoussi E, Kattamis C.
    Eur J Haematol; 2010 Oct; 85(4):335-44. PubMed ID: 20561034
    [Abstract] [Full Text] [Related]

  • 23. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major.
    Farmaki K, Tzoumari I, Pappa C, Chouliaras G, Berdoukas V.
    Br J Haematol; 2010 Feb; 148(3):466-75. PubMed ID: 19912219
    [Abstract] [Full Text] [Related]

  • 24. Treatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone.
    Porter JB, Wood J, Olivieri N, Vichinsky EP, Taher A, Neufeld E, Giardina P, Thompson A, Moore B, Evans P, Kim HY, Macklin EA, Trachtenberg F.
    J Cardiovasc Magn Reson; 2013 May 20; 15(1):38. PubMed ID: 23688265
    [Abstract] [Full Text] [Related]

  • 25. Cardiac events and cardiac T2* in Egyptian children and young adults with beta-thalassemia major taking deferoxamine.
    Elalfy MS, Abdin IA, El Safy UR, Ibrahim AS, Ebeid FS, Salem DS.
    Hematol Oncol Stem Cell Ther; 2010 May 20; 3(4):174-8. PubMed ID: 21150236
    [Abstract] [Full Text] [Related]

  • 26. Deferiprone chelation therapy for thalassemia major.
    Galanello R, Campus S.
    Acta Haematol; 2009 May 20; 122(2-3):155-64. PubMed ID: 19907153
    [Abstract] [Full Text] [Related]

  • 27. Comparison of deferiprone and deferrioxamine for the treatment of transfusional iron overload in children with beta thalassemia major.
    Waheed N, Ali S, Butt MA.
    J Ayub Med Coll Abbottabad; 2014 May 20; 26(3):297-300. PubMed ID: 25671931
    [Abstract] [Full Text] [Related]

  • 28. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.
    Totadri S, Bansal D, Bhatia P, Attri SV, Trehan A, Marwaha RK.
    Pediatr Blood Cancer; 2015 Sep 20; 62(9):1592-6. PubMed ID: 25820920
    [Abstract] [Full Text] [Related]

  • 29. Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients.
    Cassinerio E, Orofino N, Roghi A, Duca L, Poggiali E, Fraquelli M, Zanaboni L, Cappellini MD.
    Blood Cells Mol Dis; 2014 Sep 20; 53(3):164-7. PubMed ID: 24846580
    [Abstract] [Full Text] [Related]

  • 30. Deferiprone versus deferoxamine in sickle cell disease: results from a 5-year long-term Italian multi-center randomized clinical trial.
    Calvaruso G, Vitrano A, Di Maggio R, Ballas S, Steinberg MH, Rigano P, Sacco M, Telfer P, Renda D, Barone R, Maggio A, Investigators of the Multicenter Randomized Clinical Trial of Deferiprone versus Deferoxamine in Sickle-Cell-Disease.
    Blood Cells Mol Dis; 2014 Dec 20; 53(4):265-71. PubMed ID: 24814618
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Effects of combined deferiprone and deferoxamine chelation therapy on iron load indices in beta-thalassemia.
    Tsironi M, Assimakopoulos G, Polonofi K, Rigaki K, Aessopos A.
    Hemoglobin; 2008 Dec 20; 32(1-2):29-34. PubMed ID: 18274980
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Sequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: main findings and clinical follow-up of a large multicenter randomized clinical trial in -thalassemia major patients.
    Pantalone GR, Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F, Filosa A, Romeo MA, Magnano C, Caruso V, Argento C, Gerardi C, Campisi S, Violi P, Malizia R, Cianciulli P, Rizzo M, D'Ascola DG, Quota A, Prossomariti L, Fidone C, Rigano P, Pepe A, D'Amico G, Morabito A, Gluud C.
    Hemoglobin; 2011 Dec 20; 35(3):206-16. PubMed ID: 21599433
    [Abstract] [Full Text] [Related]

  • 35. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
    Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Roughton M, Assomull R, Nair SV, Walker JM, Pennell DJ.
    Circulation; 2007 Apr 10; 115(14):1876-84. PubMed ID: 17372174
    [Abstract] [Full Text] [Related]

  • 36. Combined iron chelation therapy.
    Galanello R, Agus A, Campus S, Danjou F, Giardina PJ, Grady RW.
    Ann N Y Acad Sci; 2010 Aug 10; 1202():79-86. PubMed ID: 20712777
    [Abstract] [Full Text] [Related]

  • 37. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
    Kontoghiorghe CN, Kontoghiorghes GJ.
    Drug Des Devel Ther; 2016 Aug 10; 10():465-81. PubMed ID: 26893541
    [Abstract] [Full Text] [Related]

  • 38. Recent developments in iron chelation therapy.
    Cario H, Janka-Schaub G, Janssen G, Jarisch A, Strauss G, Kohne E.
    Klin Padiatr; 2007 Aug 10; 219(3):158-65. PubMed ID: 17525910
    [Abstract] [Full Text] [Related]

  • 39. Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols.
    Kolnagou A, Economides C, Eracleous E, Kontoghiorghes GJ.
    Hemoglobin; 2008 Aug 10; 32(1-2):41-7. PubMed ID: 18274982
    [Abstract] [Full Text] [Related]

  • 40. Role of vitamin C as an adjuvant therapy to different iron chelators in young β-thalassemia major patients: efficacy and safety in relation to tissue iron overload.
    Elalfy MS, Saber MM, Adly AA, Ismail EA, Tarif M, Ibrahim F, Elalfy OM.
    Eur J Haematol; 2016 Mar 10; 96(3):318-26. PubMed ID: 26018112
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.